Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Receives FDA Fast Track Designation for Ebola Drug


Tekmira Pharmaceuticals this week announced that it has received a fast track designation for its phase I Ebola virus drug TKM-Ebola from the US Food and Drug Administration.

The designation is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need, according to the FDA. The developers of eligible drugs may receive, among other things, more frequent meetings and correspondence with agency officials.

In January, Tekmira began testing TKM-Ebola in a phase I study. Data from the trial is expected in the second half of the year.